Generate Biomedicines, Inc. (GENB) · Insider trading
What Generate Biomedicines's directors, officers and largest holders bought and sold themselves, from the Form 4 each of them files with the SEC within two business days of a trade. Open-market purchases and sales first: those are the trades somebody chose to make at the market price.
Bought, 12 months
$150.30M
5 insiders, 12 trades
Sold, 12 months
$16,000
1 insider, 100% under a plan
Net, 12 months
+$150.28M
bought less sold
Latest filing
2026-09-03
filings read to 2026-10-19
Who traded, two years
| Insider | Bought | Sold | Trades | Last trade | Holds after |
|---|---|---|---|---|---|
| Afeyan NoubarDirector, 10% owner | $150.00M | – | 6 | 2026-03-02 | – |
| Nally MichaelDirector, Chief Executive Officer | $240,000 | – | 1 | 2026-03-04 | 572,707 |
| Silvers JasonPresident & CFO | $32,000 | – | 3 | 2026-03-02 | – |
| Mendillo Jane LDirector | $24,000 | – | 1 | 2026-03-02 | 1,500 |
| Arnold FrancesDirector | – | $16,000 | 1 | 2026-09-01 | 231,472 |
| Grous BethChief People Officer | $4,800 | – | 1 | 2026-03-02 | – |
Open-market purchases and sales
Newest first. “Plan” marks a trade made under a 10b5-1 plan set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Holds after | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-01 | Arnold FrancesDirector | Saleplan | 1,000 | 16.00 | $16,000 | 231,472 | Form 4 |
| 2026-03-04 | Nally MichaelDirector, Chief Executive Officer | Buy | 20,000 | 12.00 | $240,000 | 572,707 | Form 4 |
| 2026-03-02 | Afeyan NoubarDirector, 10% ownerwith Flagship Pioneering Fund VI, L.P., Flagship VentureLabs VI LLC, Flagship Pioneering Special Opportunities Fund II, L.P., Nutritional Health Ltp Fund, L.P., Flagship Pioneering Fund Vii, L.P., Fpn II, L.P. | Buyindirect | 1,562,500 | 16.00 | $25.00M | 15,264,724 | Form 4 |
| 2026-03-02 | Afeyan NoubarDirector, 10% ownerwith Flagship Pioneering Fund VI, L.P., Flagship VentureLabs VI LLC, Flagship Pioneering Special Opportunities Fund II, L.P., Nutritional Health Ltp Fund, L.P., Flagship Pioneering Fund Vii, L.P., Fpn II, L.P. | Buyindirect | 1,562,500 | 16.00 | $25.00M | 4,340,252 | Form 4 |
| 2026-03-02 | Afeyan NoubarDirector, 10% ownerwith Flagship Pioneering Fund VI, L.P., Flagship VentureLabs VI LLC, Flagship Pioneering Special Opportunities Fund II, L.P., Nutritional Health Ltp Fund, L.P., Flagship Pioneering Fund Vii, L.P., Fpn II, L.P. | Buyindirect | 1,562,500 | 16.00 | $25.00M | 1,562,500 | Form 4 |
| 2026-03-02 | Mendillo Jane LDirector | Buy | 1,500 | 16.00 | $24,000 | 1,500 | Form 4 |
| 2026-03-02 | Afeyan NoubarDirector, 10% ownerwith Flagship Pioneering, LLC, Flagship Pioneering Fund VI General Partner LLC, Nutritional Health Ltp Fund General Partner LLC, Flagship Pioneering Fund Vii General Partner LLC, Flagship Pioneering Special Opportunities Fund II General Partner LLC, Fpn General Partner LLC, Flagship VentureLabs VI Manager LLC | Buyindirect | 1,562,500 | 16.00 | $25.00M | 15,264,724 | Form 4 |
| 2026-03-02 | Afeyan NoubarDirector, 10% ownerwith Flagship Pioneering, LLC, Flagship Pioneering Fund VI General Partner LLC, Nutritional Health Ltp Fund General Partner LLC, Flagship Pioneering Fund Vii General Partner LLC, Flagship Pioneering Special Opportunities Fund II General Partner LLC, Fpn General Partner LLC, Flagship VentureLabs VI Manager LLC | Buyindirect | 1,562,500 | 16.00 | $25.00M | 4,340,252 | Form 4 |
| 2026-03-02 | Afeyan NoubarDirector, 10% ownerwith Flagship Pioneering, LLC, Flagship Pioneering Fund VI General Partner LLC, Nutritional Health Ltp Fund General Partner LLC, Flagship Pioneering Fund Vii General Partner LLC, Flagship Pioneering Special Opportunities Fund II General Partner LLC, Fpn General Partner LLC, Flagship VentureLabs VI Manager LLC | Buyindirect | 1,562,500 | 16.00 | $25.00M | 1,562,500 | Form 4 |
| 2026-03-02 | Silvers JasonPresident & CFO | Buyindirect | 500 | 16.00 | $8,000 | 500 | Form 4 |
| 2026-03-02 | Silvers JasonPresident & CFO | Buyindirect | 500 | 16.00 | $8,000 | 500 | Form 4 |
| 2026-03-02 | Silvers JasonPresident & CFO | Buyindirect | 1,000 | 16.00 | $16,000 | 1,000 | Form 4 |
| 2026-03-02 | Grous BethChief People Officer | Buyindirect | 300 | 16.00 | $4,800 | 300 | Form 4 |
Grants, exercises and other transactions
Pay, tax and paperwork rather than a choice to trade at the market price. Two years.
12 × conversion
Show them
| Date | Insider | What | Shares | Price | Holds after | Filing |
|---|---|---|---|---|---|---|
| 2026-03-02 | Afeyan NoubarDirector, 10% owner | Conversion C | +12,723,940 | – | 12,723,940 | Form 4 |
| 2026-03-02 | Afeyan NoubarDirector, 10% owner | Conversion C | +13,702,224 | – | 13,702,224 | Form 4 |
| 2026-03-02 | Afeyan NoubarDirector, 10% owner | Conversion C | +987,491 | – | 987,491 | Form 4 |
| 2026-03-02 | Afeyan NoubarDirector, 10% owner | Conversion C | +2,777,752 | – | 2,777,752 | Form 4 |
| 2026-03-02 | Afeyan NoubarDirector, 10% owner | Conversion C | +2,777,752 | – | 2,777,752 | Form 4 |
| 2026-03-02 | Bancel StephaneDirector | Conversion C | +724,160 | – | 724,160 | Form 4 |
| 2026-03-02 | Nally MichaelDirector, Chief Executive Officer | Conversion C | +658,327 | – | 1,316,654 | Form 4 |
| 2026-03-02 | Afeyan NoubarDirector, 10% owner | Conversion C | +12,723,940 | – | 12,723,940 | Form 4 |
| 2026-03-02 | Afeyan NoubarDirector, 10% owner | Conversion C | +13,702,224 | – | 13,702,224 | Form 4 |
| 2026-03-02 | Afeyan NoubarDirector, 10% owner | Conversion C | +987,491 | – | 987,491 | Form 4 |
| 2026-03-02 | Afeyan NoubarDirector, 10% owner | Conversion C | +2,777,752 | – | 2,777,752 | Form 4 |
| 2026-03-02 | Afeyan NoubarDirector, 10% owner | Conversion C | +2,777,752 | – | 2,777,752 | Form 4 |
How to read it
- Buy, sale
- Code P and S on the form: shares bought or sold in the market, at the market price. The other codes are mostly pay (a grant, an option exercised) or tax (shares the company withheld), and say little about what the insider thinks of the price.
- Plan
- A sale or purchase under a Rule 10b5-1 plan, set up in advance and running on its own schedule. Since April 2023 the form has a box for it. Much executive selling is planned and says more about diversifying than about the company.
- Holds after
- The shares the insider still held after the trade, in the form the trade was in (directly, or indirectly through a trust or a fund).
- Value
- Shares times the price the form reports, which is often an average over several fills on the day.
Read from the SEC's own quarterly data sets of Forms 3, 4 and 5, and from each day's filings since the last one. A correcting amendment replaces the lines it restates. Every row links to its filing. None of this is advice: insiders sell for many reasons, and buy for fewer.